

The Manager
Company Announcements Office
ASX Limited

LBT GRANTED FIRST U.S. PATENT FOR APAS® TECHNOLOGY

Adelaide, 26 March 2015: Australian medical technology company LBT Innovations Limited (ASX: LBT) has been awarded the first U.S. patent for its pioneering culture-plate analysis technology, the Automated Plate Assessment System (APAS®).

Patent no. 8,896,706 relates to a novel method for 'colour calibrating' images captured by the APAS technology, which will make it easier for devices using APAS to accurately classify the colours of both bacterial colonies and culture mediums (e.g. agar).

The patent, which expires on 25 November 2034, is the first in a family of five patents for which LBT has applied to the U.S. Patent & Trademark Office, to safeguard the intellectual property associated with its core intelligent imaging technology.

"This patent is a key milestone in the journey we have recently begun to launch APAS in the United States, which represents a critical testing ground for new medical devices as well as the world's largest commercial medical market," said LBT's CEO, Mrs Lusia Guthrie.

LBT is preparing to commence a major clinical trial of the APAS technology at TriCore Reference Laboratories in Albuquerque, New Mexico, as part of its application for registration by the U.S. Food and Drug Administration (FDA). The trial will be the third and final trial of the clinical efficacy of APAS, following successful trials in Melbourne and Adelaide late last year.

– ENDS –

About LBT Innovations

LBT Innovations (LBT) is an Australian developer of clinical and diagnostic technology. Based in Adelaide, South Australia, the Company has two breakthrough products in microbiology automation: PREVI® Isola, which provides automation of culture plate streaking, and APAS®, a breakthrough in automated culture plate reading, interpretation and reporting. LBT also has a third product in development, Woundvue™, a proposed automation solution to assist in the management of chronic wounds.

Based on LBT's innovative intelligent image interpretative platform, APAS specifically addresses the automated imaging, analysis and interpretation of culture plates following incubation. LBT has entered into a Joint Venture with Hettich AG Switzerland to drive the commercial development and global distribution of APAS instrumentation and software products.

For more information, see www.lbtinnovations.com

CONTACTS

LBT Innovations	Media Relations
Lusia Guthrie CEO Tel: +61 (0)8 8227 1555 E: info@lbtinnovations.com	Rudi Michelson Monsoon Communications Tel: +61 (0)3 9620 3333 E: rudim@monsoon.com.au